---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-26-000044"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:57:00.460210+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates

## Summary
- VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.
- Net income $55.9M ($1.83 diluted EPS) vs $35.7M ($1.20) in Q1 2025; cash $1.0B.
- FDA granted platform technology designation for KB407 (CF) and KB111 (HHD) program vectors.
- KB803 (DEB corneal abrasions) fully enrolled; top-line data expected 4Q 2026. KB801 (NK) data before year end.
- FY 2026 non-GAAP R&D+SG&A guidance $175-195M; KB407 open-label study starting, KB111 HALITE-1 initiating.

## SEC filing metadata
- accession: 0001711279-26-000044
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/0001711279-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/krys-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-26-000044
- JSON: https://secwatch.observer/filing/0001711279-26-000044.json
- Plain text: https://secwatch.observer/filing/0001711279-26-000044.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported first quarter ending March 31, 2026 results: revenue $116.4 million.
  - Period: first quarter ending March 31, 2026
  - Revenue: $116.4 million
  - Result: reported results
  source text: Krystal Biotech Announces First Quarter 2026 Financial and Operating Results $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/0001711279-26-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.